About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

By: via Business Wire

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelzTM. This cutting-edge therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals dealing with brittle Type 1 diabetes, a condition characterized by extreme fluctuations in blood glucose levels.

CELZ-101, also known as Supercharged Treg Biologic Immunotherapy (ImmCelzTM), represents a state-of-the-art approach in personalized medicine, utilizing the patient's own regulatory T cells (Tregs) to combat autoimmune and alloimmune responses that can destroy insulin-producing cells. This innovative therapy is based on a proprietary process that not only expands Tregs but also enhances their functionality, offering a promising solution to reduce the need for lifelong immunosuppression.

Timothy Warbington, CEO of Creative Medical Technology Holdings, stated, "The FDA's Orphan Drug Designation for CELZ-101 underscores our commitment to developing groundbreaking therapies. This important milestone propels us closer to offering a lasting solution for those grappling with the everyday hurdles of brittle Type 1 diabetes, marked by erratic fluctuations in glucose levels. It harmonizes with our mission to better patients' lives through the forefront of regenerative medicine. "

Dr. Courtney Bartlett, DNP, AGACNP-BC, CCRP, Director of Clinical Development, commented, "The development of CELZ-101 is a major step forward in the realm of cell-based immunotherapy. It addresses the critical need for more effective treatments in brittle Type 1 diabetes by aiming for operational tolerance in islet cell transplantation, potentially freeing patients from the burden of lifelong immunosuppression. We believe this is the first orphan designated, synergistic cell-based immunotherapy for brittle Type 1 diabetes."

“The Orphan Drug Designation by the FDA highlights CELZ-101's potential to meet a significant unmet need in the prevention of allograft rejection during pancreatic islet cell transplantation which was recently approved by the FDA. This designation provides multiple important benefits to support the therapy's development including tax advantages, user fee exemptions, and the opportunity for market exclusivity following approval,” added Timothy Warbington, CEO of the Company.

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is dedicated to progressing CELZ-101 through the necessary regulatory pathways, with the goal of transforming the therapeutic landscape for patients in need of islet transplantation. This achievement underscores the company's dedication to leveraging the natural regenerative capabilities of the human body to create lasting health solutions.

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a biotechnology company dedicated to the advancement of identifying and translating novel, immediately deployable FDA registered, biological therapeutics in the fields of immunotherapy, endocrinology, urology, gynecology and orthopedics and is traded on NASDAQ under the ticker symbol CELZ.

Creative Medical Technology Holdings is at the vanguard of regenerative medicine, focusing on the development and commercialization of breakthrough therapies for unmet medical needs. With a robust portfolio of innovative treatments, Creative Medical Technology Holdings is reshaping the future of healthcare by marrying advanced scientific research with the body's natural healing mechanisms.

For further information about the Company, please visit www.creativemedicaltechnology.com.

Special Note Regarding Forward Looking Statements

NASDAQ Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

Contacts

More News

View More
3 Healthcare Stocks Using AI to Drive Growth
Via MarketBeat
Topics Artificial Intelligence
Tickers BSX HIMS TEM
Get Exposure to Millennials' Purchasing Power With This ETF
Via MarketBeat
Topics ETFs
Tickers AAPL DASH DIS GOOGL META MILN
Why a $4.5 Billion Smart Debt Move Is Fueling Dell’s AI Ambitions
Via MarketBeat
Topics Artificial Intelligence
Tickers DELL
Beam Global Gets Buy Rating With 101% Upside Potential
Via MarketBeat
Topics Intellectual Property
Tickers BEEM
These 3 Crypto Stocks Could Get a Bump as Dollar Trust Weakens
Via MarketBeat
Topics ETFs Economy World Trade
Tickers BITF COIN HOOD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.